Kunming Longjin Pharmaceutical Co Ltd (002750) — Tangible Net Worth Ratio
Kunming Longjin Pharmaceutical Co Ltd (002750) has a Tangible Net Worth Ratio of 84.7% as of March 2025. This metric is calculated by deducting intangible assets (CN¥74.01 Million) from net assets (CN¥485.19 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See 002750 working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Kunming Longjin Pharmaceutical Co Ltd Tangible Net Worth Ratio (2011–2024)
This chart shows how Kunming Longjin Pharmaceutical Co Ltd's Tangible Net Worth Ratio has changed across 14 annual periods from 2011 to 2024. As of March 2025, the ratio stands at 84.7%, reflecting net assets of CN¥485.19 Million with intangible assets of CN¥74.01 Million CNY. See Kunming Longjin Pharmaceutical Co Ltd liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Annual Tangible Net Worth Ratio for Kunming Longjin Pharmaceutical Co Ltd (2011–2024)
The table below presents the year-by-year Tangible Net Worth Ratio for Kunming Longjin Pharmaceutical Co Ltd from 2011 to 2024, covering 14 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see Kunming Longjin Pharmaceutical Co Ltd stock valuation.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 88.2% | CN¥494.21 Million | CN¥58.20 Million | CN¥574.40 Million | ▼ -1.3 pp |
| 2023 | 89.5% | CN¥541.13 Million | CN¥56.81 Million | CN¥631.63 Million | ▼ -3.1 pp |
| 2022 | 92.6% | CN¥604.77 Million | CN¥44.99 Million | CN¥747.21 Million | ▼ -0.5 pp |
| 2021 | 93.0% | CN¥678.29 Million | CN¥47.18 Million | CN¥827.28 Million | ▼ -0.3 pp |
| 2020 | 93.4% | CN¥704.71 Million | CN¥46.70 Million | CN¥841.76 Million | ▲ +0.9 pp |
| 2019 | 92.5% | CN¥665.89 Million | CN¥50.12 Million | CN¥806.89 Million | ▼ -2.8 pp |
| 2018 | 95.3% | CN¥655.93 Million | CN¥31.02 Million | CN¥787.55 Million | ▼ -1.9 pp |
| 2017 | 97.2% | CN¥645.54 Million | CN¥18.38 Million | CN¥785.23 Million | ▼ 0.0 pp |
| 2016 | 97.2% | CN¥670.46 Million | CN¥18.90 Million | CN¥759.68 Million | ▲ +0.4 pp |
| 2015 | 96.8% | CN¥599.41 Million | CN¥19.41 Million | CN¥698.86 Million | ▲ +3.7 pp |
| 2014 | 93.1% | CN¥285.57 Million | CN¥19.85 Million | CN¥435.59 Million | ▼ -0.2 pp |
| 2013 | 93.3% | CN¥302.00 Million | CN¥20.36 Million | CN¥442.56 Million | ▲ +2.5 pp |
| 2012 | 90.8% | CN¥226.94 Million | CN¥20.87 Million | CN¥368.05 Million | ▲ +2.3 pp |
| 2011 | 88.5% | CN¥186.74 Million | CN¥21.38 Million | CN¥287.36 Million | — |